FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045779784> ?p ?o ?g. }

• W2045779784 endingPage "306" @default.
• W2045779784 startingPage "301" @default.
• W2045779784 abstract "A collaborative multicenter double-blind, placebo-controlled trial of intravenous acyclovir treatment of first-episode genital herpes was performed in order to substantiate previous findings on the efficacy and safety of this drug, to evaluate the influence of parenteral therapy on recurrence frequency, and to obtain further data on the natural history of genital herpes.Eighty-two patients with first episodes of genital herpes simplex virus (HSV) infection were randomly assigned in a double-blind fashion to treatment with intravenous acyclovir (5 mg/kg every eight hours) or placebo for five days. Before therapy, all lesions in the genital/perineal area and in extragenital sites were cultured. New lesions appearing in both areas after the onset of therapy were cultured separately. Lesions in all groups were cultured until completely healed. Sera were collected from all patients on entry to the study and on Day 21 to determine presence or absence of antibodies to HSV-1 and HSV-2. Time to healing, time to crusting, time to cessation of viral shedding, and appearance of new lesions during therapy were compared for each treatment group.Patients receiving acyclovir experienced a significant reduction in the median duration of pain (4.3 versus 4.8 days, p = 0.019), viral shedding (1.9 versus 8.4 days, p less than 0.001), and time to healing (8.4 versus 11.5 days, p = 0.02) compared with placebo recipients. These differences were largely attributable to the effect of therapy in the subset of patients with primary disease in whom acyclovir reduced the median duration of pain from 10.6 days to 4.2 days, the median duration of viral shedding from 17.1 days to 1.9 days, and the median time to healing from 14.2 days to 8.3 days. The rate of subsequent recurrence of genital herpes was not altered by acyclovir treatment: 24 of 32 acyclovir recipients (75 percent) experienced one or more recurrences during a mean follow-up of 14 months compared with 19 of 27 placebo recipients (70 percent). Among patients experiencing recurrences, the mean number of recurrences per month among acyclovir recipients was 0.25 compared with 0.19 for patients given placebo.This multicenter trial confirms the efficacy of intravenous acyclovir in the management of first-episode genital herpes, especially in patients with primary infection. However, therapy did not alter the frequency of recurrences." @default.
• W2045779784 created "2016-06-24" @default.
• W2045779784 creator A5004180463 @default.
• W2045779784 creator A5008155172 @default.
• W2045779784 creator A5008280183 @default.
• W2045779784 creator A5008616473 @default.
• W2045779784 creator A5011374275 @default.
• W2045779784 creator A5012297706 @default.
• W2045779784 creator A5013714399 @default.
• W2045779784 creator A5022971416 @default.
• W2045779784 creator A5040153216 @default.
• W2045779784 creator A5042068923 @default.
• W2045779784 creator A5053679896 @default.
• W2045779784 creator A5090552119 @default.
• W2045779784 date "1988-09-01" @default.
• W2045779784 modified "2023-10-14" @default.
• W2045779784 title "Intravenous acyclovir therapy of first episodes of genital herpes: A multicenter double-blind, placebo-controlled trial" @default.
• W2045779784 cites W1964522214 @default.
• W2045779784 cites W1999509238 @default.
• W2045779784 cites W2020130616 @default.
• W2045779784 cites W2034160182 @default.
• W2045779784 cites W2051944675 @default.
• W2045779784 cites W2086675506 @default.
• W2045779784 cites W2137855972 @default.
• W2045779784 cites W2165312158 @default.
• W2045779784 cites W2320783858 @default.
• W2045779784 cites W2338896046 @default.
• W2045779784 cites W4252017411 @default.
• W2045779784 doi "https://doi.org/10.1016/0002-9343(88)90578-5" @default.
• W2045779784 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3046350" @default.
• W2045779784 hasPublicationYear "1988" @default.
• W2045779784 type Work @default.
• W2045779784 sameAs 2045779784 @default.
• W2045779784 citedByCount "32" @default.
• W2045779784 countsByYear W20457797842016 @default.
• W2045779784 countsByYear W20457797842017 @default.
• W2045779784 countsByYear W20457797842020 @default.
• W2045779784 countsByYear W20457797842021 @default.
• W2045779784 countsByYear W20457797842023 @default.
• W2045779784 crossrefType "journal-article" @default.
• W2045779784 hasAuthorship W2045779784A5004180463 @default.
• W2045779784 hasAuthorship W2045779784A5008155172 @default.
• W2045779784 hasAuthorship W2045779784A5008280183 @default.
• W2045779784 hasAuthorship W2045779784A5008616473 @default.
• W2045779784 hasAuthorship W2045779784A5011374275 @default.
• W2045779784 hasAuthorship W2045779784A5012297706 @default.
• W2045779784 hasAuthorship W2045779784A5013714399 @default.
• W2045779784 hasAuthorship W2045779784A5022971416 @default.
• W2045779784 hasAuthorship W2045779784A5040153216 @default.
• W2045779784 hasAuthorship W2045779784A5042068923 @default.
• W2045779784 hasAuthorship W2045779784A5053679896 @default.
• W2045779784 hasAuthorship W2045779784A5090552119 @default.
• W2045779784 hasConcept C126322002 @default.
• W2045779784 hasConcept C12914427 @default.
• W2045779784 hasConcept C141071460 @default.
• W2045779784 hasConcept C142724271 @default.
• W2045779784 hasConcept C16005928 @default.
• W2045779784 hasConcept C168563851 @default.
• W2045779784 hasConcept C183021626 @default.
• W2045779784 hasConcept C203014093 @default.
• W2045779784 hasConcept C204787440 @default.
• W2045779784 hasConcept C2522874641 @default.
• W2045779784 hasConcept C27081682 @default.
• W2045779784 hasConcept C2775965419 @default.
• W2045779784 hasConcept C2776409557 @default.
• W2045779784 hasConcept C2778498788 @default.
• W2045779784 hasConcept C2779450786 @default.
• W2045779784 hasConcept C2780727368 @default.
• W2045779784 hasConcept C2781196997 @default.
• W2045779784 hasConcept C2909813250 @default.
• W2045779784 hasConcept C2991744798 @default.
• W2045779784 hasConcept C2992435398 @default.
• W2045779784 hasConcept C54355233 @default.
• W2045779784 hasConcept C71924100 @default.
• W2045779784 hasConcept C86803240 @default.
• W2045779784 hasConcept C90924648 @default.
• W2045779784 hasConceptScore W2045779784C126322002 @default.
• W2045779784 hasConceptScore W2045779784C12914427 @default.
• W2045779784 hasConceptScore W2045779784C141071460 @default.
• W2045779784 hasConceptScore W2045779784C142724271 @default.
• W2045779784 hasConceptScore W2045779784C16005928 @default.
• W2045779784 hasConceptScore W2045779784C168563851 @default.
• W2045779784 hasConceptScore W2045779784C183021626 @default.
• W2045779784 hasConceptScore W2045779784C203014093 @default.
• W2045779784 hasConceptScore W2045779784C204787440 @default.
• W2045779784 hasConceptScore W2045779784C2522874641 @default.
• W2045779784 hasConceptScore W2045779784C27081682 @default.
• W2045779784 hasConceptScore W2045779784C2775965419 @default.
• W2045779784 hasConceptScore W2045779784C2776409557 @default.
• W2045779784 hasConceptScore W2045779784C2778498788 @default.
• W2045779784 hasConceptScore W2045779784C2779450786 @default.
• W2045779784 hasConceptScore W2045779784C2780727368 @default.
• W2045779784 hasConceptScore W2045779784C2781196997 @default.
• W2045779784 hasConceptScore W2045779784C2909813250 @default.
• W2045779784 hasConceptScore W2045779784C2991744798 @default.
• W2045779784 hasConceptScore W2045779784C2992435398 @default.
• W2045779784 hasConceptScore W2045779784C54355233 @default.
• W2045779784 hasConceptScore W2045779784C71924100 @default.

• next